Timolol Eye Drops in the Treatment of Acute Migraine Headache
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT02630719|
Recruitment Status : Recruiting
First Posted : December 15, 2015
Last Update Posted : October 26, 2017
|Condition or disease||Intervention/treatment|
|Migraine||Drug: Timolol eye drops Drug: Artificial tears|
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||100 participants|
|Intervention Model:||Parallel Assignment|
|Official Title:||Timolol Eye Drops in the Treatment of Acute Migraine Headache|
|Study Start Date :||January 2016|
|Estimated Primary Completion Date :||June 2018|
|Estimated Study Completion Date :||June 2018|
Experimental: timolol eye drops
Treatment with timolol eye drops at the onset of an acute migraine headache
Drug: Timolol eye drops
Placebo Comparator: Placebo eye drop
Treatment with artificial eye drops at the onset of an acute migraine headache
Drug: Artificial tears
- Timolol Eye Drops in the Treatment of Acute Migraine Headache [ Time Frame: 1 year ]
Subjects will maintain a headache diary that records time of headache onset or recurrence. Each headache occurrence will be given a headache intensity rating based on a four point scale recommended by the International Headache Society (0=no headache, 1=mild headache, 2=moderate headache, 3=severe headache).
Also recorded for each headache will be the extent of functional impairment on a four point scale (0=function and work normally, 1=mild impairment, 2=severe impairment, 3=requiring bed rest).
Any associated symptoms (eg, nausea, vomiting, photophobia, phonophobia), headache recurrences, uses of rescue medications, and adverse events will be recorded in the headache diary.
At followup visits (1 month, 3 month, 6 month and 1 year), subjects will rate the overall effectiveness of the medication on a four point scale (0=poor, 1=fair, 2=good, 3=execellent).
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT02630719
|Contact: Matthew Cossack, MDemail@example.com|
|Contact: Sean Gratton, MD||816-404-1000||Sean.Gratton@tmcmed.org|
|United States, Missouri|
|Truman Medical Center||Recruiting|
|Kansas City, Missouri, United States, 64108|
|Principal Investigator:||Sean Gratton, MD||UMKC|